Myriad Genetics, Inc. operates as a specialty molecular diagnostic laboratories worldwide. Molecular Diagnostic Testing The company’s molecular diagnostic tests are designed to analyze genes, their expression levels and corresponding proteins to assess an individual’s risk for developing disease later in life, accurately diagnose disease, determine a patient’s likelihood of responding to a particular drug, or assess a patient’s risk of disease progression and disease recurrence. myRisk Hereditary Cancer-DNA sequencing test for assessing the risks for hereditary cancers. The company’s myRisk Hereditary Cancer test represents its existing hereditary cancer testing franchise. myRisk Hereditary Cancer is designed to determine a patient’s hereditary cancer risk for breast cancer, ovarian cancer, colon cancer, uterine cancer, melanoma, pancreatic cancer, prostate cancer and gastric cancer. The test analyzes 25 separate genes to look for deleterious mutations that would put a patient at a substantially higher risk than the general population for developing one or more of the above cancers. All 25 genes in the panel are well documented in clinical literature for the role they play in hereditary cancer and have been shown to have actionable clinical interventions for the patient to lower disease risk or risk of cancer recurrence. The myRisk report presents the myRisk Genetic Test Result and myRisk Management Tool that summarizes published management guidelines related to the patient’s genetic mutation, as well as their personal and family history of cancer. myRisk Hereditary Cancer testing identifies more mutation carriers than BRACAnalysis and COLARIS combined. myRisk Hereditary Cancer was initially released through an early access launch that began in September 2013. BRACAnalysis-DNA sequencing test for assessing the risk of developing breast and ovarian cancer. The company’s BRACAnalysis test is an analysis of the BRCA1 and BRCA2 genes for assessing a woman’s risk of developing hereditary breast and ovarian cancer. Additionally, BRACAnalysis might be used to assist patients already diagnosed with breast or ovarian cancer and their physicians in determining the most appropriate therapeutic interventions to address their disease. BART-DNA sequencing test for hereditary breast and ovarian cancer. The company’s BART test is based on proprietary technology for detecting large genomic rearrangements in the genes involved in hereditary breast and ovarian cancer patients. BRACAnalysis CDx-DNA sequencing test for use as a companion diagnostic with the PARP inhibitor Lynparza (olaparib) indicated for use in identifying ovarian cancer patients with deleterious or suspected deleterious germline BRCA variants eligible for treatment with Lynparza. Tumor BRACAnalysis CDx-DNA sequencing test designed to be utilized to predict response to DNA damaging agents, such as platinum based chemotherapy agents and poly ADP ribose (PARP) inhibitors. Tumor BRACAnalysis CDx looks at both germline and somatic mutations in the BRCA1 and BRCA2 genes giving a more complete picture of potential loss of DNA repair ability within the tumor. The test is only offered through the company’s European laboratory in Munich Germany. COLARIS-DNA sequencing test for assessing the risk of colorectal and uterine cancer. The company’s COLARIS test is an analysis of the MLH1, MSH2, MSH6, PMS2, EPCAM and MYH genes for assessing a person’s risk of developing colorectal and uterine cancer. Individuals who carry a deleterious mutation in one of the colon cancer genes in the COLARIS test have a greater than 80% lifetime risk of developing colon cancer and women have up to a 71% lifetime chance of developing uterine cancer. Colon cancer is a preventable disease if high-risk individuals diligently have colonoscopies and remove any precancerous polyps. COLARIS AP-DNA sequencing test for assessing the risk of colorectal cancer. The company’s COLARIS AP test detects mutations in the APC and MYH genes, which cause a colon polyp-forming syndrome such as familial adenomatous polyposis (FAP), a more common variation of the syndrome known as attenuated FAP, and the
myriad genetics inc (MYGN:NASDAQ GS)
320 Wakara Way
Salt Lake City, UT 84108
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for MYGN.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact MYRIAD GENETICS INC, please visit www.myriad.com. Company data is provided by Capital IQ. Please use this form to report any data issues.